ժҪĿ�� Ӧ�óɱ�-Ч�������������ٴ�ҩѧ��������������������߸��������ݸ˾�(HP)���Ƶľ���ѧ��ֵ������ ǰհ������2015��7��~2016��6����Ժ�����ڿ�������ﻼ��96��,�����Ϊ�������Ԥ��,�������賣���������,��Ԥ������ҩ��������á����ٴ�ҩʦ����ʱ��ɱ���Ϊֱ�ӳɱ�,�ٴ�ҩʦ��ѵ����Ϊ��ӳɱ�,�����������������֡�HP�����ʺ�θ����֢״������ΪЧ��ָ��,�����ٴ�ҩѧ����ijɱ�-Ч����������� ���ٴ�ҩѧ�����Ԥ��,��Ԥ����ҩ���������ֵ�����������ڶ�����(1.71 vs. 0.44,P<0.01),��Ԥ��θ����֢״����44��,������36��(91.67% vs. 75.00%,P=0.028);��Ԥ��HP�������������ڶ�����(91.67% vs. 72.92%,P=0.016)���ڴ�ҽԺ�Ƕ�,�������ٴ�ҩʦ����ɱ�Ϊ292.31Ԫ,��Ԥ��Ϊ821.61Ԫ,����529.30Ԫ���۸�Ԥ�����������ҩ�����Է���ijɱ�-Ч����Ϊ480.47,������Ϊ664.34,���л�������ѧ����,��Ԥ�������HP�����ʺ���θ����֢״����ɱ�-Ч���ȸ��ڶ�����,�����гɱ�/Ч�������� ��չ�ٴ�ҩѧ����������ҽԺ�ɱ�,�ɱ�-Ч��������ʾ���������ҩ�����Է������һ���Ļ������塣
Abstract��OBJECTIVE To assess the cost-effectiveness of clinical pharmaceutical care in the H. pylori(HP) eradication in outpatients with peptic ulcer.METHODS Ninty-six Outpatients with HP positive peptic ulcer from July 2015 to June 2016 were prospectively collected, and randomly divide into control group and intervention group. Patients in the control group were given the traditional outpatient service. The intervention group patients were given with pharmaceutical education and follow-up by clinical pharmacist. The score of compliance with medication, HP eradication rate and the improvement of gastrointestinal symptom were selected as outcome indicator. Time cost of intervention and fee of clinical pharmacist training were estimated and recorded as the cost of clinical pharmacy intervention. RESULTS ��Improvement of the score of compliance with medication of intervention group patients was significantly higher than the control group (1.71 vs. 0.44, P<0.01). Forty-four patients of the intervention group, while 36 patients in the control group reported less gastrointestinal symptoms (91.67% vs. 75.00%, P=0.028). The HP eradication rate of the intervention group was significantly higher than the control group (91.67% vs. 72.92%, P=0.016). ��For the hospital, the cost of pharmacy service of control group was 292.31 yuan, and 821.61 yuan of the intervention group. ��The cost-effectiveness ratio of the score of compliance with medication of control group was 664.34, while the intervention group was 480.47, which was superior to the control group. It was cost-effective. However, the cost-effectiveness ratio of HP eradication rate and the improvement of gastrointestinal symptom of the intervention group were both higher than the control group. CONCLUSION Clinical pharmaceutical care increase the cost of the hosipital. However, clinical pharmaceutical care can result in cost-effective improvement of the medication compliance.
EDITORIAL BOARD OF CHINESE JOURNAL OF DIGESTION. Clinical diagnosis and treatment protocol for peptic ulcer[J] . Chin J Dig(�л�������־), 2016,36(8):508-513.
[2]
SUNG J J, KUIPERS E J, EL-SERAG H B. Systematic review: the global incidence and prevalence of peptic ulcer disease[J] . Aliment Pharmacol Ther, 2009,29(9):938-946.
[3]
LIN K J, GARCIARODRIGUEZ L A, HERNANDEZ-DIAZ S. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates?[J] . Pharmacoepidemiol Drug Saf, 2011,20(7):718-728.
[4]
KUIPERS E J, THIJS J C, FESTEN H P. The prevalence of Helicobacter pylori in peptic ulcer disease[J] . Aliment Pharmacol Ther, 1995,9(suppl 2):59-69.
[5]
MALFERTHEINER P, MEGRAUD F, O��MORAIN C A, et al. Management of Helicobacter pylori infection-the maastricht ��/florence consensus report[J] . Gut, 2012,61(5):646-664.
[6]
HU F L. Worth attention in Helicobacter pylori eradication[J] . Natl Med J China(�л�ҽѧ��־), 2013,93(44):3489-3490.
[7]
DAI Q J, SHU X L. Relevant factors analysis on pathogen eradication efficacy in patients with H. pylori-positive peptic ulcer[J] . Chin Mod Doctor(�й��ִ�ҽ��), 2013,51(12):9-11.
[8]
AL-EIDAN F A, MCELNAY J C, SCOTT M G, et al. Management of Helicobacter pylori eradication-the influence of structured counselling and follow-up[J] . Br J Clin Pharmacol, 2002,53(2):163-171.
[9]
FUNAKOSHI R, YOKOYAMA H, KAWAI N, et al. Effect of pharmaceutical care on diagnosis based on assessment of 13C-urea breath test for Helicobacter pylori infection[J] . YakugakuZasshi, 2012,132(5):601-607.
[10]
SYEDLUND J, SJODIN I, DOTEVALL G. GSRS a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease[J] . Dig Dis Sci, 1988,33(2):129-134.
[11]
YU Y X, ZHU L H, TANG L, et al. Influence of pharmaceutical care on medication compliance and treatment effect and carotid atheromatous plaque in patients with hyperlipidemia[J] . Chin Pharm J(�й�ҩѧ��־), 2014, 49(19): 1760-1762.
[12]
LIU H L, WANG H M, HE H S, et al. Perspectives on development direction of hospital pharmacy and working mode of pharmacist under the new condition of medical reform[J] . Chin Pharm J(�й�ҩѧ��־), 2015, 50(20): 1836-1840.
[13]
WANG Y, ZHOU H Q, TANG W. Helicobacter pylori resistant to antibiotic isolated in Suzhou area[J] . Chin J Public Health(���������), 2010,26(1):122-123.
[14]
KOPP B J, MRSAN M, ERSTAD B L, et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist[J] . Am J Health Syst Pharm, 2007,64(23):2483-2487.
[15]
PLUMRIDGE R J, WOJNAR-HORTON R E. A review of the pharmacoeconomics of pharmaceutical care[J] . Pharmacoeconomics, 1998,14(2):175-189.
[16]
LONG E W, HU M, TONG R S, et al. Analysis on the cost-effectiveness of pharmaceutical care for type II diabetic outpatients[J] . Chin Hosp Pharm J(�й�ҽԺҩѧ��־), 2014,34(2):139-142.
2017, Vol. 52 
